Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
You may also be interested in...
Japanese firm's decision to end development of entinostat in its licensed territories marks possibly final blow to development of the HDAC inhibitor in breast cancer.
The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.